3 results
Approved WMOCompleted
To obtain an estimate of the anterograde PCI success rate for patients with a confirmed target CTO in each treatment group and to explore safety and tolerability in these patients.
Approved WMOCompleted
Phase Ia: (dose escalation):- To determine the maximum tolerated dose (MTD) and a recommended Phase II dose (RP2D) for M3814 (also referred to as MSC2490484A) in combination with fractionated palliative radiotherapy (RT) for tumors or metastases…
Approved WMOCompleted
Primary objective: To evaluate the safety and tolerability of GSK1795091 when administered in combination with either GSK3174998, GSK3359609, orpembrolizumab.Secondary objectives: * To evaluate the antitumor activity of GSK1795091 when administered…